Arvinas (NASDAQ:ARVN) Issues Earnings Results

Arvinas (NASDAQ:ARVN) posted its quarterly earnings results on Tuesday. The company reported ($0.82) EPS for the quarter, beating the consensus estimate of ($0.92) by $0.10, Zacks reports. Arvinas had a negative net margin of 3.45% and a negative return on equity of 2.06%. The business had revenue of $0.50 million during the quarter, compared to analyst estimates of $12.39 million. During the same quarter in the previous year, the business posted ($0.48) EPS. The company’s quarterly revenue was down 98.8% compared to the same quarter last year.

Here are the key takeaways from Arvinas’ conference call:

• ARV-393 is expected to deliver initial monotherapy data at ASH in December, focused on T-cell lymphoma, with additional B-cell lymphoma, durability, and glofitamab-combination data planned for mid-2027. Management said early responses have been observed across lymphoma subtypes and views the program as potentially competitive, though most initial patients were treated below predicted efficacious exposure levels.
• The company plans to dose SBMA patients with the oral ARV-027 androgen-receptor degrader in the first half of 2027, following healthy-volunteer data. Management is targeting approximately 50% reduction in polyQ-AR, which it believes could translate into improved muscle strength and endurance based on preclinical findings.
• ARV-6723, Arvinas’ oral HPK1 degrader, has entered a Phase I monotherapy trial, with pembrolizumab combination dosing planned for the first half of 2027 and initial clinical data expected in the second half of 2027. The company highlighted preclinical activity in checkpoint-resistant models and complete tumor regressions in combination studies, but clinical validation remains pending.
• Development of the LRRK2 degrader ARV-102 remains constrained by an ongoing FDA clinical hold in the U.S.; the company now expects to initiate a Phase Ib PSP trial in Europe and the U.K. in 2027 and may add U.S. sites later. While biomarker and oculomotor findings strengthened management’s confidence, the relationship between these measures and meaningful clinical benefit is not yet established.
• Arvinas ended the quarter with $558.9 million in cash, restricted cash, and marketable securities and projects funding into the second half of 2028. Lower year-over-year R&D and G&A spending supports the runway, although the balance declined from $685.4 million at year-end 2025 and some programs may extend beyond current cash guidance.

Arvinas Stock Performance

ARVN traded down $0.25 during trading on Thursday, hitting $7.17. The stock had a trading volume of 62,590 shares, compared to its average volume of 825,949. The company has a market capitalization of $462.74 million, a PE ratio of -30.18 and a beta of 1.81. Arvinas has a twelve month low of $6.74 and a twelve month high of $14.51. The stock has a 50 day simple moving average of $7.98 and a two-hundred day simple moving average of $9.63.

Trending Headlines about Arvinas

Here are the key news stories impacting Arvinas this week:

• Positive Sentiment: HC Wainwright initiated coverage with a Buy rating and a $13 price target, well above the share price cited in the report. HC Wainwright analyst coverage
• Positive Sentiment: Arvinas plans to present preliminary Phase 1 dose-escalation data for ARV-393, its investigational BCL6 degrader. The presentation could provide investors with an update on the drug’s progress, though the report does not include results. ARV-393 clinical data presentation
• Negative Sentiment: HC Wainwright projects losses of $2.44 per share in 2027 and $2.70 in 2028, followed by further losses through 2030. Those forecasts underscore the company’s continuing earnings risk despite the bullish rating. Arvinas analyst estimates

Analyst Upgrades and Downgrades

ARVN has been the topic of a number of recent research reports. Wall Street Zen upgraded shares of Arvinas from a “sell” rating to a “hold” rating in a research note on Saturday, August 8th. Zacks Research raised shares of Arvinas from a “hold” rating to a “strong-buy” rating in a research note on Friday, October 9th. Morgan Stanley set a $10.00 target price on Arvinas in a research report on Monday, August 10th. Weiss Ratings downgraded Arvinas from a “sell (d+)” rating to a “sell (d)” rating in a report on Friday, October 23rd. Finally, BTIG Research reiterated a “buy” rating and issued a $18.00 price target on shares of Arvinas in a report on Tuesday, August 4th. One equities research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, two have given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $15.18.

About Arvinas

Arvinas, Inc is a clinical-stage biopharmaceutical company focused on developing medicines based on targeted protein degradation. The company’s proprietary PROTAC® protein degrader platform is designed to direct the body’s natural cellular machinery to selectively break down disease-causing proteins that may be difficult to address with conventional drug approaches.

Arvinas has concentrated its research and development efforts primarily on oncology, including hormone-driven cancers. Its pipeline has included vepdegestrant, an estrogen receptor protein degrader being developed for patients with estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer, as well as other investigational degraders targeting cancer-related proteins.